Ebola hemorrhagic fever
MONDO:0005737A viral hemorrhagic fever that is caused by the Ebola virus, which is transmitted by contact with infected animals or humans; it is characterized by high fever, unexplained bleeding, and a high mortality rate.
Also known as: EHF, Ebola, Ebola fever, Ebola virus disease, Ebolavirus caused disease or disorder, Ebolavirus disease or disorder, Ebolavirus infectious disease
25 clinical trials for this condition and its sub-types, 21 tagged with Ebola hemorrhagic fever itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New sudan ebola vaccine shows promise in phase 2 trial
Vaccine CompletedThis study tested a new vaccine designed to protect against Sudan ebolavirus, a close relative of the Ebola virus. Researchers gave the vaccine or a placebo to 125 healthy adults to see if it is safe and triggers an immune response. The goal is to find a way to prevent this deadl…
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Sep 13, 2026 00:00 UTC
-
Ebola vaccine trial aims to shield frontline workers in congo
Vaccine CompletedThis study tests a two-dose Ebola vaccine regimen in healthcare workers in the Democratic Republic of the Congo, who are at high risk during outbreaks. Participants receive an initial shot of Ad26.ZEBOV followed by a booster of MVA-BN-Filo 56 days later. Some will also get an add…
Phase 2 • Sponsor: Universiteit Antwerpen • Aim: Vaccine
Last updated Jul 16, 2026 00:00 UTC
-
Ebola vaccine trial targets HIV-Positive adults and teens
Vaccine CompletedThis study tested an experimental Ebola vaccine (V920) in 251 HIV-infected adults and adolescents to see if it is safe and triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels. The trial too…
Phase 2 • Sponsor: Canadian Immunization Research Network • Aim: Vaccine
Last updated Jun 27, 2026 08:10 UTC
-
Hope in a pill? ebola drug favipiravir tested in guinea
Disease control CompletedThis completed Phase 2 trial tested the antiviral drug favipiravir in 126 people with Ebola in Guinea. The goal was to see if it could reduce deaths. Participants received high doses of the drug by mouth for up to 10 days. The study aimed to find a practical treatment for Ebola, …
Phase 2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Ebola vaccine booster study aims to strengthen protection for frontline workers
Prevention CompletedThis study tested whether a booster dose of the Ebola vaccine (V920) could improve and extend immune protection in 248 healthy adults at risk of Ebola exposure through their jobs. Participants received the primary vaccine and were randomly assigned 18 months later to get a booste…
Phase 2 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Ebola's hidden toll on Kids' brains revealed years later
Knowledge-focused CompletedThis study looked at children who survived Ebola and compared them to close contacts who never got sick. Researchers checked for brain, nerve, and thinking problems more than 5 years after infection. The goal was to understand what lasting issues survivors face, not to test a tre…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Ebola survivors under the microscope: what happens after recovery?
Knowledge-focused CompletedThis completed study in the Democratic Republic of the Congo followed 787 people who survived Ebola and their close contacts. Researchers tracked their health over time, looking for lingering virus, immune responses, and other infections. The goal was to better understand the lon…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC